Asthma and Allergy Clinic, Children's Clinic Randers, Dytmaersken 9, 8900, Randers, Denmark.
Biostatistics and Clinical Data Science, Mundipharma Research GmbH & Co. KG, Limburg, Germany.
Clin Drug Investig. 2018 Apr;38(4):313-318. doi: 10.1007/s40261-017-0609-x.
For more than a decade, urinary free cortisol corrected for creatinine (OUFCC) has been used to assess the systemic bioactivity of inhaled corticosteroids in children with asthma. Paediatric normative ranges, however, have not been established. The aim of the present study was to define a preliminary range for OUFCC in Tanner stage 1 children.
A post hoc analysis was performed of 26 Tanner stage one children (aged 5-11 years) with mild asthma only requiring prn (pro re nata) treatment with short-acting β-agonists, who participated in a 3-way cross-over knemometry study. The study comprised a run-in, two washout periods and three treatment periods (2 weeks each). Urine was collected at the end of each period. A normative range was derived using the 95% prediction interval for the geometric mean OUFCC, calculated from run-in and washout periods.
Twenty-six children contributed 41 OUFCC values. The geometric mean OUFCC was 9.0 nmol/mmol (95% PI: 3.6, 22.7 nmol/mmol).
The OUFCC preliminary normative range was 3.6 to 22.7 nmol/mmol in Tanner stage one children. A larger study in healthy children is warranted to confirm these findings and to assess potential differences in OUFCC across developmental stages and age groups, and by gender and race.
2013-004719-32, CLINICALTRIALS.
NCT02063139.
十多年来,尿游离皮质醇肌酐校正(OUFCC)一直被用于评估哮喘儿童吸入皮质类固醇的全身生物活性。然而,尚未建立儿科规范范围。本研究的目的是确定 Tanner 1 期儿童 OUFCC 的初步范围。
对 26 名仅需要按需使用短效β激动剂(pro re nata)治疗的轻度哮喘 Tanner 1 期儿童(年龄 5-11 岁)进行了一项事后分析,他们参加了一项 3 向交叉肯氏法研究。该研究包括一个预试验期、两个洗脱期和三个治疗期(每个治疗期 2 周)。每个治疗期末采集尿液。使用从预试验和洗脱期计算得到的 OUFCC 几何均数的 95%预测区间,得出规范范围。
26 名儿童共提供了 41 个 OUFCC 值。OUFCC 的几何均数为 9.0 nmol/mmol(95%PI:3.6,22.7 nmol/mmol)。
Tanner 1 期儿童的 OUFCC 初步规范范围为 3.6 至 22.7 nmol/mmol。需要进行更大规模的健康儿童研究来证实这些发现,并评估 OUFCC 在不同发育阶段和年龄组、性别和种族之间的潜在差异。
EUDRACT 编号:2013-004719-32,临床试验。
GOV 标识符:NCT02063139。